

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – July 21, 2018
Data through : July 21, 2018
Table 4 – Progression to Step 2 by Site

	Overall	Baylor	Blantyre	Botha's Hill	DTTC-SU
Total Participants Enrolled ¹	151	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection ²	151	0	0	0	0
Progressed to Step 2	144/151 (95.4%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	4/151 (2.6%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	3/151 (2.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	2/151 (1.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	1/151 (0.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/151 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for
Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – July 21, 2018
Data through : July 21, 2018
Table 4 – Progression to Step 2 by Site**

	Emavundleni	Gaborone	Isipingo	Kisumu	Lilongwe
Total Participants Enrolled ¹	0	12	0	0	0
Participants who have been enrolled for 6 weeks or received injection ²	0	12	0	0	0
Progressed to Step 2	0/0 (–%)	10/12 (83.3%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
Progression Status Pending	0/0 (–%)	0/12 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
Did Not Progress to Step 2	0/0 (–%)	2/12 (16.7%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
Permanently discontinued from the study product	0/0 (–%)	2/12 (16.7%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
Terminated from the study	0/0 (–%)	0/12 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (–%)	0/12 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – July 21, 2018
Data through : July 21, 2018
Table 4 – Progression to Step 2 by Site

	MU-JHU	Parirenyatwa	Seke South	Soweto	Spilhaus
Total Participants Enrolled ¹	0	25	0	33	0
Participants who have been enrolled for 6 weeks or received injection ²	0	25	0	33	0
Progressed to Step 2	0/0 (–%)	23/25 (92.0%)	0/0 (–%)	32/33 (97.0%)	0/0 (–%)
Progression Status Pending	0/0 (–%)	2/25 (8.0%)	0/0 (–%)	0/33 (0.0%)	0/0 (–%)
Did Not Progress to Step 2	0/0 (–%)	0/25 (0.0%)	0/0 (–%)	1/33 (3.0%)	0/0 (–%)
Permanently discontinued from the study product	0/0 (–%)	0/25 (0.0%)	0/0 (–%)	0/33 (0.0%)	0/0 (–%)
Terminated from the study	0/0 (–%)	0/25 (0.0%)	0/0 (–%)	1/33 (3.0%)	0/0 (–%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (–%)	0/25 (0.0%)	0/0 (–%)	0/33 (0.0%)	0/0 (–%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – July 21, 2018
Data through : July 21, 2018
Table 4 – Progression to Step 2 by Site

	St.Mary's Clinic	Swaziland	UVRI-IAVI	Verulam	Ward 21
Total Participants Enrolled ¹	29	0	0	0	32
Participants who have been enrolled for 6 weeks or received injection ²	29	0	0	0	32
Progressed to Step 2	29/29 (100.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	31/32 (96.9%)
Progression Status Pending	0/29 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	1/32 (3.1%)
Did Not Progress to Step 2	0/29 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/32 (0.0%)
Permanently discontinued from the study product	0/29 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/32 (0.0%)
Terminated from the study	0/29 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/32 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/29 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/32 (0.0%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for
 Pre-Exposure Prophylaxis in HIV-Uninfected Women
 Report – July 21, 2018
 Data through : July 21, 2018
 Table 4 – Progression to Step 2 by Site**

	Zengeza
Total Participants Enrolled ¹	20
Participants who have been enrolled for 6 weeks or received injection ²	20
Progressed to Step 2	19/20 (95.0%)
Progression Status Pending	1/20 (5.0%)
Did Not Progress to Step 2	0/20 (0.0%)
Permanently discontinued from the study product	0/20 (0.0%)
Terminated from the study	0/20 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/20 (0.0%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.